Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0283241 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Miyuki Takasu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Introduction
High-dose chemotherapy followed by autologous stem cell transplant is the mainstay of treatment for multiple myeloma (MM). The purpose of this study was to evaluate the ability of MRI-derived indices to predict mobilized hematopoietic stem cell yield. Materials and methods In this exploratory pilot work, we retrospectively analyzed 38 mobilization procedures for MM. Successful mobilization procedure was defined as a total yield of >4.0×10 6 CD34 + cells/kg. Univariate and multivariate analyses were performed to identify factors with a significant effect on successful mobilization from among clinical characteristics including number of prior lines of therapy, period from diagnosis to harvest, type of monoclonal protein (M protein); and radiological characteristics including total diffusion volume (tDV), median apparent diffusion coefficient (ADC) of tDV, and mean fat fraction of bone marrow calculated by MRI.
Results
Univariate analyses showed that relatively poor mobilization was significantly associated with M protein of Bence-Jones type and with median ADC of tDV (P = 0.02 and P = 0.004, respectively). Multivariate analyses using these two indices showed that median ADC of tDV was a significant predictive factor for adequate mobilization (P = 0.01), with an area under the curve of 0.784 (cutoff value, 1.18×10 −3 mm 2 /s; sensitivity, 72.7%; specificity, 87.5%).
Conclusion
The present data indicate that median ADC of tDV is a predictive factor for relatively poor mobilization of hematopoietic stem cells in MM patients undergoing autologous stem cell transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Department of Diagnostic Radiology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Immune Regenerative Medicine, International Center for Cell and Gene Therapy, Research Promotion and Support Headquarters, Fujita Health University, Aichi, Japan.
- Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
- Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Miyuki Takasu
Förderung
- JSPS KAKENHI
Zitieren
APA
Takasu, M., Higashino, R., Sueoka, T., Kawai, S., Tanitame, N., Tamura, A., Iida, M., Kawase, T., Ichinohe, T., & Awai, K. (2023). Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices. PLOS ONE. https://doi.org/10.1371/journal.pone.0283241
Vancouver
Takasu M, Higashino R, Sueoka T, Kawai S, Tanitame N, Tamura A, et al. Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices. PLOS ONE. 2023. doi:10.1371/journal.pone.0283241
BibTeX
@article{Takasu2023,
author = {Takasu, Miyuki and Higashino, Ryo and Sueoka, Takahiro and Kawai, Saki and Tanitame, Nobuko and Tamura, Akihisa and Iida, Makoto and Kawase, Takakazu and Ichinohe, Tatsuo and Awai, Kazuo},
title = {Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0283241}
}
EUVIMED